Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Banner Week For Bayer In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - For the third time in a week Bayer released positive news related to Japan, saying Jan. 28 it had received marketing approval from the Ministry of Health, Labor and Welfare for Nexavar (sorafenib) for the treatment of advanced renal cell carcinoma. Four days earlier, the German company had said Nexavar received priority review from MHLW for the treatment of hepatocelluar carcinoma, a larger potential market

You may also be interested in...



Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market

BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound

Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market

BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound

Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early

Bayer and Onyx Pharmaceuticals announced Aug. 27 that a trial evaluating Nexavar (sorafenib) in Asia-Pacific patients with hepatocellular carcinoma will be stopped early to allow all patients to receive the drug based on positive study results and the recommendation of an independent data monitoring committee

Latest News
See All
UsernamePublicRestriction

Register

SC066767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel